Lactobacillus crispatus  CTV-05  (Lactin-V,  Osel) 
is  a  live  biotherapeutic  product  that  contains  a 
naturally occurring vaginal strain of L. crispatus. In previous clinical trials, no serious or grade 3 
adverse events that were considered to be related 
to the use of Lactin-V were reported.13-18 On the 
basis of the results from a phase 2a clinical trial 
of Lactin-V,16 the current phase 2b trial was de-
signed to assess whether treatment with Lactin-V 
after  a  5-day  course  of  metronidazole  to  treat 
bacterial vaginosis would result in a significantly 
lower  incidence  of  recurrence  of  bacterial  vagi-
nosis than placebo..

regimen for reevaluation of their eligibility. Among  the  partici-
pants  with  detectable  L.  crispatus  CTV-05,  the 
median  concentration  in  the  Lactin-V  group 
ranged from 1.7×106 to 6.2×106 CFU per millili-
ter during the treatment phase through week 12 . Overall,  adherence  to  the  assigned 
treatment  was  high.